Outside of the Chair, ExThera Medical Board Composed Entirely of Outside Experts
Martinez, Calif. – March 23, 2021 – Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company.
Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), vasopressors, and septic shock. He remains an active investigator in the fields of AKI biomarkers, AKI therapeutics and Acute Kidney Disease. He served as an advisor on the Defense Advanced Research Projects Agency (DARPA) $150 million Dialysis-Like Therapy Program that sought to foster emerging, pathogen agnostic blood cleansing countermeasures to respond to the outbreak of sepsis-causing infectious diseases. This program evaluated ExThera’s Seraph technology which is in active use across the United States to treat critically ill COVID-19 patients.
“Dr. Chawla is the preeminent authority on acute kidney injury, sepsis, and the possibilities that extracorporeal filters hold for patients and physicians around the world,” said ExThera Medical Chairman and CEO Robert Ward. “ExThera has already benefited greatly from Dr. Chawla’s expertise. Our efforts to provide a safe and effective device to treat COVID-19 and other emerging diseases can only be elevated by Dr. Chawla’s position on our Board of Directors.”
Dr. Chawla is the author of over 150 peer-reviewed publications and a recipient of the International Vicenza Award for Critical Care Nephrology; an award that recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide.
“Innovation in critical care is indispensable in our fight against the COVID-19 pandemic and the many other challenges posed by emerging infectious diseases,” said Dr. Chawla. “I have been delighted to work with Exthera Medical in developing smart solutions for critically ill patients and look forward to deepening our relationship and continuing to make progress toward saving lives.”
Previously, Dr. Chawla was a Professor of Medicine at the George Washington University (GWU), where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was previously the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center.
During his tenure at GWU, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Data from the ATHOS trial was published in the medical journal Critical Care during 2014. In 2015, Dr. Chawla moved from GWU to La Jolla Pharmaceutical Company (LJPC) where he joined as Chief Medical Officer. At LJPC, Dr. Chawla oversaw the development and conduct of the Phase 3 registration ATHOS-3 trial. The data from the ATHOS-3 Trial helped support the FDA approval of GIAPREZA (angiotensin II) which is indicated for the treatment of hypotension due to the treatment of septic or other distributive shock. GIAPREZA was approved on December 21, 2017 and EMA approval in August 2019. Thereafter, Dr. Chawla oversaw the Medical Affairs launch and commercialization of GIAPREZA.
# # #
About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) for removing a broad range of pathogens from the bloodstream of patients. Seraph 100 can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the U.S., the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike.
The Seraph 100 Microbind Affinity Blood Filter (Seraph 100) attained CE Mark in 2019 and is commercially available in the EU for the treatment of blood stream infections. The Seraph 100 device has neither been cleared nor approved by the U.S. Food and Drug Administration (FDA) for any indication. The Seraph 100 has been authorized by FDA under an Emergency Use Authorization (EUA) to treat patients with COVID-19 infection. The Seraph 100 is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph 100 device under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
For more information, visit the company’s website at https://extheramedical.com/.
About Seraph 100 and the ONCObind Procedure
As a patient’s blood flows through the Seraph® 100 Microbind® Affinity Filter (Seraph 100), it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph 100 adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.
ExThera Medical is currently developing the ONCObind Procedure Hemoperfusion Filter (ONCObind) to support cancer treatment. ONCObind is part of the same platform technology as Seraph 100.
For more news stories on Seraph 100 and ONCObind, click here.
Disclaimer
All information contained in this news release derives from plausible, reliable sources, however they have not been independently examined or verified. There is no representation, warranty, or guarantee provided herein. Except as otherwise required by appliable law, all liability for any direct or indirect claims, damages or losses are hereby disclaimed whether or not foreseeable. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Accordingly, the investment and/or the revenues that arise from it can rise or fall or fail entirely. We assume no responsibility to update or revise any statements contained in this news release, including forward-looking, to reflect events, trends, or circumstances that might arise after the date of this news release. Results from case studies (reviews) may not be predictive of future results.
MM0044 Rev A
MM0006 Rev E